The SWANglide ultrasound-enhanced needle biopsy from Swan Cytologics improves patient outcomes and reduces healthcare costs by solving the problems of needle biopsy inadequacy and inefficiency, making it essential for oncology care and precision medicine. It is estimated that SWANglide, once fully deployed, could create direct global healthcare savings of almost $2 billion annually while generating $350 million of annual revenue for Swan. Swan is currently seeking investors at the Seed/Series A stages.

Swan Cytologics logo



Event details

Date: September 14 - 16, 2020

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


16 in total